BioSpace News Archive

Bruker Corporation (Nasdaq: BRKR) today announced it will report fourth quarter and fiscal year 2020 financial results on Tuesday, February 16, 2021, before the market opens.

CooperSurgical announced today the acquisition of California-based, AEGEA Medical and its FDA-approved Mara™ Water Vapor Ablation System.

Cigna’s International Markets business has published its fourth COVID-19 Global Impact Study. This series, which builds on Cigna’s annual 360 Well-being Study, provides further insight into the global impact of the COVID-19 pandemic on people’s well-being in 11 markets around the globe.

Azimuth Sleep Solutions has received FDA Emergency Use Authorization(EUA) for their patent-pending PortPatch™ product, in order to expand air filtration capabilities for patient treatment options and to help keep healthcare workers safer in patient-care areas where non-invasive ventilatory treatment devices need to be used.

The National Eczema Association (NEA) today announced the publication of its research revealing the out-of-pocket costs of eczema, or atopic dermatitis (AD), for patients and caregivers in the U.S.

– Qualifies Freeze-Dried Version of LinearDNA ™ COVID-19 Vaccine Candidate Ahead of Initiation of Feline Clinical Trial – – Reconstituted Vaccine Candidate Demonstrates Potency, Validating Easy Shipment in Dry State – – Feline Clinical Trial On-Track to Begin by March 31, 2021 –

Dascena, Inc., a machine learning company, today announced that the company will present data from three different studies of its machine learning algorithms at the Society for Critical Care Medicine’s (SCCM) Annual Congress, taking place virtually from January 31 to February 12, 2021.

MustGrow’s safe and effective natural biopesticide is plant-based - harnessing the mustard seed’s natural defense mechanism to control diseases, pests, and weeds with an organic food-grade biopesticide.

COVAXX is developing the world’s first multitope protein/peptide-based vaccine to fight COVID-19, using its high precision, commercially proven and scalable vaccine platform.

Net proceeds will help support planning of clinical trials for JAN101, the company’s lead drug candidate